Lates News

Every AI briefing, Open Source Securities released a research report on November 16, giving a "buy" rating to New Zhi Bio (920685.SH). The rating reasons mainly include: 1) Q1-Q3 2025: revenue of 114 million yuan, up 5% year-on-year, net profit attributable to owners of the parent company 20.71 million yuan, down 4% year-on-year; 2) the company continues to adhere to market-driven sales strategy, setting up a wholly-owned subsidiary - Ningbo New Zhi Intelligent; 3) the global analysis instrument market space is expected to reach 114 billion US dollars by 2034, with a CAGR of 6.5%. (Daily Economic News)